PURPOSE: The aim was to investigate whether maintenance therapy (MT) is sufficient or not to improve overall survival (OS) and progress-free survival (PFS) of advanced non-small cell lung cancer (NSCLC) patients. METHODS: Randomized controlled trials (RCTs) published between 1990 and 2013 were retrieved from PubMed, EMBASE, ISTP, clinicaltrials.org, and ASCO conference proceeding. Patients' characteristics, OS, progress-free survival, and hazard ratios were extracted. Data were analyzed using RevMan 5.2. Fourteen RCTs involving 6198 individuals were included. RESULTS: Compared with placebo, observation or best supportive care (BSC), patients receiving single agent (SA) MT had an improved OS (hazard ratio, HR 0.85, 95% CI 0.79-0.91; p < 0.05) and PFS (HR 0.65, 95% CI 0.57-0.73; p < 0.05). In a sub-group analysis of SA MT versus placebo, observation or BSC, we found that switch MT using SA provided an improved OS (HR 0.85, 95% CI 0.79-0.91; p < 0.05). For multiple agent (MA) versus SA MT, a prolonged PFS (HR 0.68, 95% CI 0.52-0.88; p < 0.05) but not OS (HR 0.96, 95% CI 0.86-1.07; p > 0.05) was observed for MA. A significant prolonged PFS was observed in MA switch MT (HR 0.71, 95% CI 0.58-0.86; p < 0.05) versus SA MT. However, no significant improvement in OS was observed for MA versus SA MT, indicating that switch MT (HR 0.90, 95% CI 0.73-1.12; p > 0.05) and continuous MT (HR 0.98, 95% CI 0.86-1.11; p > 0.05) showed similar effect on OS. CONCLUSION: SA switch MT is associated with improved OS and PFS in patients with advanced NSCLC. MA switch MT is sufficient to improve PFS, but not OS.
PURPOSE: The aim was to investigate whether maintenance therapy (MT) is sufficient or not to improve overall survival (OS) and progress-free survival (PFS) of advanced non-small cell lung cancer (NSCLC) patients. METHODS: Randomized controlled trials (RCTs) published between 1990 and 2013 were retrieved from PubMed, EMBASE, ISTP, clinicaltrials.org, and ASCO conference proceeding. Patients' characteristics, OS, progress-free survival, and hazard ratios were extracted. Data were analyzed using RevMan 5.2. Fourteen RCTs involving 6198 individuals were included. RESULTS: Compared with placebo, observation or best supportive care (BSC), patients receiving single agent (SA) MT had an improved OS (hazard ratio, HR 0.85, 95% CI 0.79-0.91; p < 0.05) and PFS (HR 0.65, 95% CI 0.57-0.73; p < 0.05). In a sub-group analysis of SA MT versus placebo, observation or BSC, we found that switch MT using SA provided an improved OS (HR 0.85, 95% CI 0.79-0.91; p < 0.05). For multiple agent (MA) versus SA MT, a prolonged PFS (HR 0.68, 95% CI 0.52-0.88; p < 0.05) but not OS (HR 0.96, 95% CI 0.86-1.07; p > 0.05) was observed for MA. A significant prolonged PFS was observed in MA switch MT (HR 0.71, 95% CI 0.58-0.86; p < 0.05) versus SA MT. However, no significant improvement in OS was observed for MA versus SA MT, indicating that switch MT (HR 0.90, 95% CI 0.73-1.12; p > 0.05) and continuous MT (HR 0.98, 95% CI 0.86-1.11; p > 0.05) showed similar effect on OS. CONCLUSION:SA switch MT is associated with improved OS and PFS in patients with advanced NSCLC. MA switch MT is sufficient to improve PFS, but not OS.
Authors: Thomas Brodowicz; Maciej Krzakowski; Matjaz Zwitter; Valentina Tzekova; Rodryg Ramlau; Nicolae Ghilezan; Tudor Ciuleanu; Branka Cucevic; Kalman Gyurkovits; Ernst Ulsperger; Jacek Jassem; Mislav Grgic; Pinar Saip; Maria Szilasi; Christoph Wiltschke; Maria Wagnerova; Natalya Oskina; Victoria Soldatenkova; Christoph Zielinski; Miklos Wenczl Journal: Lung Cancer Date: 2006-03-29 Impact factor: 5.705
Authors: Fabrice Barlesi; Arnaud Scherpereel; Achim Rittmeyer; Antonio Pazzola; Neus Ferrer Tur; Joo-Hang Kim; Myung-Ju Ahn; Joachim G J V Aerts; Vera Gorbunova; Anders Vikström; Elaine K Wong; Pablo Perez-Moreno; Lada Mitchell; Harry J M Groen Journal: J Clin Oncol Date: 2013-07-08 Impact factor: 44.544
Authors: Madhusmita Behera; Taofeek K Owonikoko; Zhengjia Chen; Scott A Kono; Fadlo R Khuri; Chandra P Belani; Suresh S Ramalingam Journal: Lung Cancer Date: 2012-04-28 Impact factor: 5.705
Authors: Andrea Ardizzoni; Luca Boni; Marcello Tiseo; Frank V Fossella; Joan H Schiller; Marianne Paesmans; Davorin Radosavljevic; Adriano Paccagnella; Petr Zatloukal; Paola Mazzanti; Donald Bisset; Rafael Rosell Journal: J Natl Cancer Inst Date: 2007-06-06 Impact factor: 13.506
Authors: Alberto Caballero Vázquez; Paula García Flores; Ana Romero Ortiz; Raimundo García Del Moral; Bernardino Alcázar-Navarrete Journal: J Thorac Dis Date: 2018-09 Impact factor: 2.895
Authors: Till Plönes; Walburga Engel-Riedel; Erich Stoelben; Christina Limmroth; Oliver Schildgen; Verena Schildgen Journal: J Pers Med Date: 2016-01-15